Identification of presented SARS-CoV-2 HLA class I and HLA class II peptides using HLA peptidomics
Adi Nagler,
Shelly Kalaora,
Chaya Barbolin,
Anastasia Gangaev,
Steven L.C. Ketelaars,
Michal Alon,
Joy Pai,
Gil Benedek,
Yfat Yahalom-Ronen,
Noam Erez,
Polina Greenberg,
Gal Yagel,
Aviyah Peri,
Yishai Levin,
Ansuman T. Satpathy,
Erez Bar-Haim,
Nir Paran,
Pia Kvistborg,
Yardena Samuels
Affiliations
Adi Nagler
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
Shelly Kalaora
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
Chaya Barbolin
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
Anastasia Gangaev
Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, the Netherlands
Steven L.C. Ketelaars
Division of Molecular Oncology and Immunology, the Netherlands Cancer Institute, the Netherlands
Michal Alon
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
Joy Pai
Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
Gil Benedek
Tissue Typing and Immunogenetics Unit, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel
Yfat Yahalom-Ronen
Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel
Noam Erez
Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel
Polina Greenberg
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
Gal Yagel
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
Aviyah Peri
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel
Yishai Levin
The de Botton Institute for Protein Profiling, The Nancy and Stephen Grand Israel National Center for Personalized Medicine, Weizmann Institute of Science, Rehovot, Israel
Ansuman T. Satpathy
Department of Pathology, Stanford University School of Medicine, Stanford, CA, USA
Erez Bar-Haim
Department of Biochemistry and Molecular Genetics, Israel Institute for Biological Research, Ness Ziona, Israel
Nir Paran
Department of Infectious Diseases, Israel Institute for Biological Research, Ness Ziona, Israel
Pia Kvistborg
Tissue Typing and Immunogenetics Unit, Hadassah Medical Organization and Faculty of Medicine, Hebrew University of Jerusalem, Israel
Yardena Samuels
Department of Molecular Cell Biology, Weizmann Institute of Science, Rehovot, Israel; Corresponding author
Summary: The human leukocyte antigen (HLA)-bound viral antigens serve as an immunological signature that can be selectively recognized by T cells. As viruses evolve by acquiring mutations, it is essential to identify a range of presented viral antigens. Using HLA peptidomics, we are able to identify severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-derived peptides presented by highly prevalent HLA class I (HLA-I) molecules by using infected cells as well as overexpression of SARS-CoV-2 genes. We find 26 HLA-I peptides and 36 HLA class II (HLA-II) peptides. Among the identified peptides, some are shared between different cells and some are derived from out-of-frame open reading frames (ORFs). Seven of these peptides were previously shown to be immunogenic, and we identify two additional immunoreactive peptides by using HLA multimer staining. These results may aid the development of the next generation of SARS-CoV-2 vaccines based on presented viral-specific antigens that span several of the viral genes.